Sparfloxacin versus clarithromycin in the treatment of community- acquired pneumonia

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 103-117

  Ramirez, Julio ^a   Unowsky, Joel ^b   Talbot, George H ^b   Zhang, Hao ^b   Townsend, Lloyd ^b  

^a University of Louisville School of Medicine   (United States)

^b SANOFI   (France)

Author keywords

Clarithromycin; Community acquired pneumonia; Sparfloxacin

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; MACROLIDE; QUINOLONE; SPARFLOXACIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY; PNEUMONIA; QT INTERVAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0033048131     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88271-5     Document Type: Article

References (18)

1. 1. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-1426.
2. 2. Meeker DP, Longworth DL. Community-acquired pneumonia: An update. Clevel Clin J Med. 1996;63:16-30.
3. 3. Bartlett JG, Mundy LM. Community-acquired pneumonia. NEJM. 1995;333:1618-1624.
4. 4. Metlay JP, Schulz R, Li Y-H, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med. 1997;157:1453-1459.
5. 5. Gómez J, Banos V, Ruiz Gómez J, et al. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1996;15:556-560.
6. 6. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275:134-141.
7. 7. King DE, Pippin HJ Jr. Community-acquired pneumonia in adults: Initial antibiotic therapy. Am Fam Phys. 1997; 56:544-550.
8. 8. Goa KL, Bryson HM, Markham A. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs. 1997;53:700-725.
9. 9. Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother. 1996;37(Suppl A):57-63.
10. 10. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother. 1996;37(Suppl A):145-160.
11. 11. Lipsky BA, Dorr MB, Magner DJ, Talbot GH. Safety profile of sparfloxacin in North American phase III clinical trials. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996: New Orleans, Louisiana.. Abstract LM13.
12. 12. Portier H, May T, Proust A, and the French Study Group. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1996;37(Suppl A):83-91.
13. 13. Donowitz GR, Brandon ML, Salisbury JP, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: A randomized, double-masked, comparative, multicenter study. Clin Ther. 1997;19:936-953.
14. 14. Ginesu F, Pirina P, Deiola G, et al. Etiology and therapy of community-acquired pneumonia. J Chemother. 1997;9:285-292.
15. 15. Bohte R, van Furth R, van den Broek PJ. Actiology of community-acquired pneumonia: A prospective study among adults requiring admission to hospital. Thorax. 1995;50:543-547.
16. 16. Ballow CH, Jones RN, Schentag JJ, et al. Synercid (quinupristin/dalfopristin; Q/D) antimicrobial features assessed by a multicenter study in the USA: Interim report. Presented at the 20th International Congress of Chemotherapy; June 29-July 3, 1997; Sydney, Australia.
17. 17. Coley CM, Li Y-H, Medsger AR, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med. 1996;156:1565-1571.
18. 18. Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis. 1995;22:219-223.